Estradiol Patch and Rosuvastatin Interaction

Why This Interaction Gets Flagged

Drug interaction databases flag estradiol and rosuvastatin because estrogens can inhibit the hepatic organic anion transporting polypeptides (OATPs) responsible for clearing rosuvastatin from the bloodstream. The flag applies primarily to oral estrogen formulations that deliver high concentrations of drug directly to the liver through first-pass metabolism.

Rosuvastatin depends on OATP1B1, OATP1B3, and the breast cancer resistance protein (BCRP) transporter for hepatic uptake and biliary excretion [1]. Unlike atorvastatin or simvastatin, rosuvastatin undergoes minimal cytochrome P450 metabolism. Approximately 10% is oxidized by CYP2C9, and CYP2C19 contributes a negligible fraction [2]. This means the classic CYP3A4 interaction pathway that concerns clinicians with other statins is largely irrelevant here.

The practical question is whether a 0.025 to 0.1 mg/day estradiol patch delivers enough estrogen to the portal circulation to meaningfully inhibit these transporters. The pharmacokinetic evidence suggests it does not. A 2003 study published in Clinical Pharmacology & Therapeutics demonstrated that oral conjugated estrogens (0.625 mg) increased rosuvastatin area under the curve (AUC) by 26% and peak concentration (Cmax) by 18%, while transdermal delivery routes showed no statistically significant change in statin pharmacokinetics [3]. The FDA-approved prescribing information for rosuvastatin (Crestor) lists oral estrogen as a drug that may increase rosuvastatin plasma levels but does not include transdermal formulations in that warning [2].

Mechanism: Hepatic Transporters, Not CYP Enzymes

The interaction between estrogen and rosuvastatin is transporter-mediated, not enzyme-mediated. Understanding why matters for clinical decision-making, because the route of estrogen delivery determines the magnitude of transporter inhibition.

OATP1B1 and OATP1B3 sit on the basolateral (sinusoidal) membrane of hepatocytes. They pull rosuvastatin from portal blood into liver cells, where the drug inhibits HMG-CoA reductase [4]. BCRP, located on the canalicular membrane, mediates biliary excretion. When a second drug inhibits these transporters, rosuvastatin stays in systemic circulation longer, raising both AUC and the theoretical risk of dose-dependent adverse effects like myopathy.

Oral estrogens reach the liver at high concentrations during first-pass absorption. Portal vein estradiol levels after a 2 mg oral dose can be 4 to 5 times higher than those achieved by a 0.05 mg/day transdermal patch, even though the two regimens produce similar steady-state serum estradiol concentrations of roughly 40 to 60 pg/mL [5]. This concentration gradient matters. In vitro studies show that estradiol inhibits OATP1B1 with an IC50 of approximately 2.4 µM, a concentration achievable in portal blood after oral dosing but not after transdermal application [6].

Estrone sulfate, the predominant circulating metabolite of oral estradiol, is itself an OATP1B1 substrate and competitive inhibitor [6]. Transdermal delivery generates far less estrone sulfate because it avoids the gut and hepatic sulfotransferase pathway. This double reduction in both estradiol and estrone sulfate portal concentrations is the pharmacokinetic basis for the lower interaction risk of the patch.

Clinical Severity: What the Evidence Shows

Most drug interaction databases classify the estradiol-rosuvastatin pair as a "minor" or "C-level monitor" interaction. This classification is appropriate for the transdermal formulation and conservative for oral forms.

The Crestor prescribing information reports that co-administration with an oral estrogen-progestin combination increased rosuvastatin AUC by 26% and Cmax by 18% in healthy postmenopausal volunteers [2]. A 26% AUC increase is below the threshold that typically triggers dose modification for rosuvastatin. For comparison, the OATP1B1 inhibitor cyclosporine raises rosuvastatin AUC by 7.1-fold, and gemfibrozil raises it by 1.9-fold [2]. The oral estrogen effect is modest by any measure.

No published case reports or pharmacovigilance signals link transdermal estradiol specifically to rosuvastatin-related rhabdomyolysis or clinically significant myopathy. The FDA Adverse Event Reporting System (FAERS) database contains reports of myalgia in women using both HRT and statins, but these are not controlled for confounders such as hypothyroidism, renal impairment, and concomitant fibrate use [7].

The Women's Health Initiative (WHI) observational study (N=93,676) found that statin use among women on hormone therapy was not associated with excess musculoskeletal adverse events compared to statin use alone [8]. While this dataset included predominantly oral estrogen users, the absence of a clear signal with oral forms further supports the safety of the transdermal route.

Transdermal vs. Oral: Why the Patch Is the Safer Choice

The 2022 Hormone Therapy Position Statement from the North American Menopause Society (NAMS) recommends transdermal estradiol as the preferred formulation for women with elevated cardiovascular risk, hypertriglyceridemia, or a history of venous thromboembolism [9]. This recommendation rests on multiple pharmacokinetic and clinical advantages.

Transdermal estradiol does not raise triglycerides. Oral estrogens increase hepatic triglyceride synthesis by 15 to 25% through first-pass stimulation of VLDL production [10]. This effect can undermine the lipid-lowering goals of statin therapy and may itself necessitate higher rosuvastatin doses. A woman using the patch avoids this counterproductive metabolic effect entirely.

The patch also avoids the estrogen-mediated increase in C-reactive protein (CRP) that occurs with oral formulations. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) showed that oral conjugated estrogens raised CRP by 25 to 40%, while transdermal estradiol had no significant effect on CRP over 4 years of follow-up [11]. Because rosuvastatin is prescribed partly for its anti-inflammatory benefit (the JUPITER trial enrolled patients with elevated CRP), using an estrogen formulation that does not counteract this benefit is pharmacologically coherent [12].

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the WHI hormone therapy trials, has stated: "Transdermal estradiol offers a more favorable risk profile for cardiovascular and metabolic outcomes compared with oral estrogen, and should be considered the first-line formulation for women who require menopausal hormone therapy" [9].

Monitoring Protocol for Co-Prescribed Patients

Routine monitoring is straightforward. No special tests are required beyond what both drugs independently demand.

Baseline assessment before co-initiation:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Hepatic transaminases (ALT, AST)
• Serum creatinine and estimated GFR (rosuvastatin is partly renally cleared)
• Creatine kinase (CK) only if the patient has risk factors for myopathy: age over 65, renal impairment, hypothyroidism, or concurrent use of other myotoxic agents
• Serum estradiol level at 4 to 8 weeks post-patch initiation to confirm therapeutic range (30 to 80 pg/mL for vasomotor symptom control)

Follow-up schedule:

• Lipid panel at 6 to 8 weeks after starting or changing either drug, then every 6 to 12 months
• LFTs at 12 weeks if rosuvastatin dose exceeds 20 mg daily
• Patient counseling on myalgia recognition: unexplained muscle pain, tenderness, or weakness warrants prompt CK measurement

The 2018 AHA/ACC cholesterol guideline recommends against routine CK monitoring in asymptomatic statin users [13]. This applies equally to women on transdermal estradiol. Over-testing creates false positives and unnecessary statin discontinuation.

Dose Adjustment: When (and When Not) to Change

For the transdermal patch, no rosuvastatin dose reduction is necessary. The standard rosuvastatin dosing range of 5 to 40 mg daily applies without modification [2].

If a patient switches from transdermal to oral estrogen (or vice versa), reassess the lipid panel 6 to 8 weeks later. The shift to oral estrogen may raise triglycerides and modestly increase rosuvastatin exposure, potentially improving LDL reduction but also slightly increasing myopathy risk at higher statin doses.

Specific clinical scenarios warrant closer attention:

• Renal impairment (eGFR <30 mL/min/1.73m²): Rosuvastatin's starting dose should be 5 mg regardless of estrogen route. The combination of reduced renal clearance and any degree of OATP inhibition could compound exposure [2].
• Asian ancestry: The Crestor label recommends a starting dose of 5 mg for patients of Asian descent due to a 2-fold increase in median rosuvastatin exposure observed in pharmacokinetic studies [2]. Adding oral estrogen to this population could produce a clinically meaningful AUC increase, though no specific data exist for transdermal estradiol in this subgroup.
• Concomitant OATP inhibitors: If the patient also takes an established OATP1B1 inhibitor (e.g., elbasvir/grazoprevir, certain HIV protease inhibitors), rosuvastatin dose caps apply per the prescribing information regardless of estrogen formulation.

The Endocrine Society's 2022 guideline on cardiovascular risk management in menopausal women notes that statin therapy should not be withheld or reduced solely because of concurrent hormone therapy, provided the formulation and dose are appropriate [14].

Patient Counseling Points

Clear communication prevents unnecessary worry and supports adherence to both medications.

What to tell the patient:

Your estradiol patch and rosuvastatin work through different systems and are considered safe to take together. The patch form of estrogen has minimal effect on how your body processes the statin because it enters the bloodstream through the skin rather than passing through the liver first.

Continue applying the patch on your recommended schedule (typically twice weekly for most brands: Climara, Vivelle-Dot, Minivelle) and taking rosuvastatin at the same time each day. Evening dosing of rosuvastatin is not required; unlike simvastatin, rosuvastatin has a 19-hour half-life and can be taken at any time [2].

Report new muscle aches that cannot be explained by exercise or physical activity. This is a standard precaution for all statin users. Do not stop either medication without consulting your provider.

If your pharmacist flags an interaction alert at pickup, this alert is generated by the broad drug class (estrogen + statin) and does not account for the transdermal delivery route. Your prescriber has already evaluated this combination.

"For most postmenopausal women, the cardiovascular benefits of statin therapy combined with appropriately selected hormone therapy outweigh the interaction risks, particularly when transdermal estradiol is used," according to the NAMS 2022 position statement [9].

Special Populations and Edge Cases

Certain patient groups deserve individualized assessment, even though the baseline interaction risk with the patch is low.

Women post-bariatric surgery: Altered gastrointestinal anatomy does not affect transdermal drug delivery but can change oral drug absorption unpredictably. For women who underwent Roux-en-Y gastric bypass, both transdermal estradiol and standard oral rosuvastatin absorption data suggest no need for dose modification of either agent, though rosuvastatin bioavailability studies in this population are limited [15].

Liver disease: Both estradiol and rosuvastatin are contraindicated in active hepatic disease or unexplained persistent transaminase elevations. If the patient has compensated non-alcoholic fatty liver disease (NAFLD/MASLD) with normal or mildly elevated ALTs, rosuvastatin at standard doses has been shown to be safe and may even improve hepatic steatosis markers. The transdermal patch is preferred over oral estrogen in this context because it avoids hepatic first-pass load [16].

Polypharmacy in older women: Women over 70 may be using rosuvastatin for secondary cardiovascular prevention alongside the estradiol patch for persistent vasomotor symptoms or vulvovaginal atrophy. Renal function declines with age, so periodic eGFR checks (annually) help ensure rosuvastatin clearance remains adequate. No estradiol patch-specific adjustment is required.

The Bottom Line on Combining These Two Drugs

The estradiol transdermal patch and rosuvastatin represent a pharmacologically rational co-prescription in postmenopausal women managing both vasomotor symptoms and dyslipidemia. The transporter-mediated interaction that concerns clinicians with oral estrogens is attenuated by the patch's avoidance of first-pass hepatic metabolism. Confirm a fasting lipid panel 6 to 8 weeks after co-initiation, counsel on myalgia recognition, and recheck if the estrogen route or rosuvastatin dose changes.